Roche and Artery Therapeutics, a biotechnology company based in San Francisco, are collaborating to develop ApoA-I peptide mimetics for the treatment of cardiovascular disease. Financial terms were not disclosed.

The Appellate Court of Dsseldorf in Germany has found that Medtronics CoreValve transcatheter aortic valve system does not infringe Edwards Lifesciences German Andersen patent for its transcatheter heart valve technology, set to expire in May 2011.

Edwards Lifesciences board of directors has authorized a share repurchase program to acquire up to $500 million of its outstanding common shares.

Cardiac Science has initiated a worldwide voluntary recall after determining that approximately 12,200 automated external defibrillators (AEDs) may not be able to deliver therapy during a resuscitation attempt, which may lead to serious adverse events or death.

Edwards Lifesciences, a provider of products to treat advanced cardiovascular disease, has reported strong income and sales gains in the fourth quarter of 2009, as well as the 2009 fiscal year, mainly bolstered by an uptick in heart valve sales.

When officials at Howard Memorial Hospital in Nashville, Ark., started drawing up plans for a new facility that opened in July 2009, Cindy York, the hospitals director of radiology, had to make some decisions.

Eli Lilly has reported its 2009 fourth quarter and fiscal year financial returns, reversing net losses into substantial net income gains.

Cardiologists ranked Merck's sales representatives second, a noteworthy increase from sixth place in 2008, while Pfizer was ranked first by cardiologists, according to the 2009 Ranking Tables Study from healthcare market research firm SDI.